Drug Profile


Alternative Names: GT-2331; Perceptin

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gliatech (CEASED)
  • Class Antidementias; Antihistamines; Neuroprotectants; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Sleep disorders

Most Recent Events

  • 02 Feb 2017 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 02 Feb 2017 Discontinued - Phase-II for Attention-deficit hyperactivity disorder in USA (PO)
  • 02 Feb 2017 Discontinued - Phase-II for Cognition disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top